108 related articles for article (PubMed ID: 8224391)
1. Hydroxypyridinones and desferrioxamine inhibit macrophage-mediated LDL oxidation by iron but not by copper.
Lamb DJ; Hider RC; Leake DS
Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):234S. PubMed ID: 8224391
[No Abstract] [Full Text] [Related]
2. [Effect of cytochrome P-450 inhibitors on oxidative modification of low-density lipoproproteins by macrophages].
Dushkin MI; Zenkov NK; Men'shikova EB; Pivovarova EN; Liubimov GIu; Vol'skiĭ NN
Vopr Med Khim; 1996; 42(1):23-30. PubMed ID: 8783470
[TBL] [Abstract][Full Text] [Related]
3. Acidic pH increases the oxidation of LDL by macrophages.
Morgan J; Leake DS
FEBS Lett; 1993 Nov; 333(3):275-9. PubMed ID: 8224192
[TBL] [Abstract][Full Text] [Related]
4. Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity.
Naves Díaz ML; Elorriaga R; Canteros A; Cannata Andía JB
Nephrol Dial Transplant; 1998; 13 Suppl 3():23-8. PubMed ID: 9568816
[TBL] [Abstract][Full Text] [Related]
5. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
Brock JH; Licéaga J; Arthur HM; Kontoghiorghes GJ
Am J Hematol; 1990 May; 34(1):21-5. PubMed ID: 2327400
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Kontoghiorghes GJ
Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
[TBL] [Abstract][Full Text] [Related]
7. Effect of iron salts, haemosiderins, and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay.
Anderson D; Yardley-Jones A; Vives-Bauza C; Chua-Anusorn W; Cole C; Webb J
Teratog Carcinog Mutagen; 2000; 20(5):251-64. PubMed ID: 10992272
[TBL] [Abstract][Full Text] [Related]
8. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
Sheppard LN; Kontoghiorghes GJ
Arzneimittelforschung; 1993 Jun; 43(6):659-63. PubMed ID: 8352819
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica.
Lesic B; Foulon J; Carniel E
Antimicrob Agents Chemother; 2002 Jun; 46(6):1741-5. PubMed ID: 12019084
[TBL] [Abstract][Full Text] [Related]
10. Effect of iron-chelator deferiprone on the in vitro growth of staphylococci.
Kim CM; Shin SH
J Korean Med Sci; 2009 Apr; 24(2):289-95. PubMed ID: 19399272
[TBL] [Abstract][Full Text] [Related]
11. Antimalarial effect of iron chelators.
Gordeuk VR; Loyevsky M
Adv Exp Med Biol; 2002; 509():251-72. PubMed ID: 12572998
[No Abstract] [Full Text] [Related]
12. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).
Fernández-Martín JL; Menéndez-Fraga P; Canteros MA; Díaz-López JB; Cannata-Andía JB
Clin Chim Acta; 1994 Oct; 230(2):137-45. PubMed ID: 7834865
[TBL] [Abstract][Full Text] [Related]
13. Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.
Maclean KH; Cleveland JL; Porter JB
Blood; 2001 Dec; 98(13):3831-9. PubMed ID: 11739193
[TBL] [Abstract][Full Text] [Related]
14. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
15. Competition studies of L1-deferiprone with copper and iron. Possible implications on efficacy, toxicity and new therapeutic applications.
Pashalidis I; Kontoghiorghes GJ
Transfus Sci; 2000 Dec; 23(3):259-61. PubMed ID: 11099910
[No Abstract] [Full Text] [Related]
16. Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1).
Matthews AJ; Vercellotti GM; Menchaca HJ; Bloch PH; Michalek VN; Marker PH; Murar J; Buchwald H
J Surg Res; 1997 Nov; 73(1):35-40. PubMed ID: 9441790
[TBL] [Abstract][Full Text] [Related]
17. Iron chelation in chemotherapy.
Weinberg ED
Adv Appl Microbiol; 2003; 52():187-208. PubMed ID: 12964245
[No Abstract] [Full Text] [Related]
18. Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein.
Lamb DJ; Leake DS
FEBS Lett; 1994 Jan; 338(2):122-6. PubMed ID: 8307168
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin.
Georgiou NA; van der Bruggen T; Oudshoorn M; Nottet HS; Marx JJ; van Asbeck BS
J Infect Dis; 2000 Feb; 181(2):484-90. PubMed ID: 10669330
[TBL] [Abstract][Full Text] [Related]
20. Effect of oral iron chelator L1 on iron absorption in man.
Dresow B; Fischer R; Nielsen P; Gabbe EE; Piga A
Ann N Y Acad Sci; 1998 Jun; 850():466-8. PubMed ID: 9668586
[No Abstract] [Full Text] [Related]
[Next] [New Search]
